Literature DB >> 14656884

Long-term outcome after bone marrow transplantation for severe aplastic anemia.

Lionel Ades1, Jean-Yves Mary, Marie Robin, Christèle Ferry, Raphael Porcher, Hélène Esperou, Patricia Ribaud, Agnès Devergie, Richard Traineau, Eliane Gluckman, Gérard Socié.   

Abstract

From January 1978 to December 2001, 133 patients with severe aplastic anemia (SAA) underwent non-T cell-depleted allogeneic bone marrow transplantation from an HLA-identical sibling donor, at the Hospital Saint Louis using either the combination of cyclophosphamide (Cy) and thoracoabdominal irradiation (TAI; n=100) or Cy and antithymocyte globulin (ATG; n=33), as a conditioning regimen. With 13.6 years of follow-up, the 10-year survival estimate was 64%. Four factors were associated with lower survival: older age, use of Cy-TAI, any form of treatment prior to transplantation (either androgens or immunosuppressive therapy, [IST]), and grade II to IV acute graft-versus-host disease (GvHD). TAI was the sole factor associated with the occurrence of acute GvHD. The risk of cancers (15-year cumulative incidence, 10.9%) was associated with older age and with the use of cyclosporine as IST before transplantation. Cumulative incidences and risk factors of nonmalignant late effect including avascular osteonecrosis and late bacterial, viral, and fungal infection were also analyzed. Improved results using Cy-ATG as conditioning can lead to more than 90% chance of cure in patients with SAA. Even if, in our experience, the role of Cy-ATG versus that of Cy-TAI remained inextricably related to the year of transplantation, the major detrimental role of the GvHD disease in the long-term outcome and its relation to TAI supports avoidance of irradiation in the conditioning regimen. Furthermore, avoidance of any IST before transplantation in patients with a sibling donor is a prerequisite for attaining such excellent results.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656884     DOI: 10.1182/blood-2003-07-2546

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

Review 2.  The diagnosis and treatment of aplastic anemia: a review.

Authors:  Maurizio Miano; Carlo Dufour
Journal:  Int J Hematol       Date:  2015-04-03       Impact factor: 2.490

3.  Bilateral breast lumps in a patient after sex mismatched allogeneic transplantation for aplastic anaemia.

Authors:  A K Enjeti; M Seldon; S Braye
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

Review 4.  Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis.

Authors:  Ronit Gurion; Anat Gafter-Gvili; Mical Paul; Liat Vidal; Isaac Ben-Bassat; Moshe Yeshurun; Ofer Shpilberg; Pia Raanani
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

5.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.

Authors:  Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

6.  Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.

Authors:  Yoshihiro Inamoto; Mary E D Flowers; Tao Wang; Alvaro Urbano-Ispizua; Michael T Hemmer; Corey S Cutler; Daniel R Couriel; Amin M Alousi; Joseph H Antin; Robert Peter Gale; Vikas Gupta; Betty K Hamilton; Mohamed A Kharfan-Dabaja; David I Marks; Olle T H Ringdén; Gérard Socié; Melhem M Solh; Görgün Akpek; Mitchell S Cairo; Nelson J Chao; Robert J Hayashi; Taiga Nishihori; Ran Reshef; Ayman Saad; Ami Shah; Takanori Teshima; Martin S Tallman; Baldeep Wirk; Stephen R Spellman; Mukta Arora; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-30       Impact factor: 5.742

Review 7.  Aplastic Anemia.

Authors:  Neal S Young
Journal:  N Engl J Med       Date:  2018-10-25       Impact factor: 91.245

8.  Patient features and survival of pediatric aplastic anemia in the USA: a large institution experience.

Authors:  M J Hossain; S Xie
Journal:  J Public Health (Oxf)       Date:  2019-06-01       Impact factor: 2.341

9.  TLI in pediatric patients.

Authors:  A Ocanto; A Escribano; L Glaría; I Rodríguez; C Ferrer; C Huertas; A Pérez; R Morera
Journal:  Clin Transl Oncol       Date:  2019-09-21       Impact factor: 3.405

10.  Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.

Authors:  Phillip Scheinberg; Colin O Wu; Olga Nunez; Neal S Young
Journal:  J Pediatr       Date:  2008-07-30       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.